Clinical trialNCT05918640RecruitingPhase 1/PHASE2Interventional

Lurbinectedin in FET-Fused Tumors

SponsorChildren's Hospital of PhiladelphiaEnrollment63Desmoplastic Small Round Cell TumorEwing SarcomaPediatric CancerUndifferentiated Sarcoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to find out if a drug called lurbinectedin (the "study drug") is safe and effective at treating people with recurrent or relapsed solid tumors, including Ewing sarcoma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Theodore Laetsch, MD
Children's Hospital of Philadelphia
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

Cedars-Sinai Medical Center
Los Angeles, California, United States
Recruiting
University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
Jenna Gedminas, MD
Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Steven Dubois, MD
Recruiting
University of Michigan
Ann Arbor, Michigan, United States
Rashmi Chugh, MD
Recruiting
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Julia Glade Bender, MD
Recruiting
Children'S Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Lurbinectedin →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 27 Jul 2023
Primary completion: 30 Jul 2027
Completion: 30 Jul 2028
Last update posted: 31 Mar 2026
Registered enrollment: 63
Registry id: NCT05918640

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.